이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
uniQure 관리
관리 기준 확인 1/4
uniQure's CEO는 Matt Kapusta, Dec2016 에 임명되었습니다 의 임기는 7.67 년입니다. 총 연간 보상은 $ 6.58M, 9.6% 로 구성됩니다. 9.6% 급여 및 90.4% 보너스(회사 주식 및 옵션 포함). 는 $ 2.21M 가치에 해당하는 회사 주식의 0.67% 직접 소유합니다. 2.21M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 6.9 년입니다.
주요 정보
Matt Kapusta
최고 경영자
US$6.6m
총 보상
| CEO 급여 비율 | 9.6% |
| CEO 임기 | 7.8yrs |
| CEO 소유권 | 0.7% |
| 경영진 평균 재임 기간 | 1.9yrs |
| 이사회 평균 재임 기간 | 7yrs |
최근 관리 업데이트
Recent updates
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03
uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$285m |
| Mar 31 2024 | n/a | n/a | -US$297m |
| Dec 31 2023 | US$7m | US$635k | -US$308m |
| Sep 30 2023 | n/a | n/a | -US$228m |
| Jun 30 2023 | n/a | n/a | -US$187m |
| Mar 31 2023 | n/a | n/a | -US$157m |
| Dec 31 2022 | US$6m | US$609k | -US$127m |
| Sep 30 2022 | n/a | n/a | -US$125m |
| Jun 30 2022 | n/a | n/a | -US$114m |
| Mar 31 2022 | n/a | n/a | US$324m |
| Dec 31 2021 | US$5m | US$583k | US$330m |
| Sep 30 2021 | n/a | n/a | US$321m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | -US$139m |
| Dec 31 2020 | US$4m | US$585k | -US$125m |
| Sep 30 2020 | n/a | n/a | -US$166m |
| Jun 30 2020 | n/a | n/a | -US$136m |
| Mar 31 2020 | n/a | n/a | -US$124m |
| Dec 31 2019 | US$4m | US$548k | -US$124m |
| Sep 30 2019 | n/a | n/a | -US$105m |
| Jun 30 2019 | n/a | n/a | -US$103m |
| Mar 31 2019 | n/a | n/a | -US$92m |
| Dec 31 2018 | US$3m | US$502k | -US$83m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$78m |
| Mar 31 2018 | n/a | n/a | -US$78m |
| Dec 31 2017 | US$4m | US$468k | -US$79m |
보상 대 시장: Matt 의 총 보상 ($USD 6.58M )은 US 시장( $USD 2.41M ).
보상과 수익: 회사가 수익성이 없는 동안 Matt 의 보상이 증가했습니다.
CEO
Matt Kapusta (52 yo)
7.8yrs
테뉴어
US$6,584,919
보상
Mr. Matthew Craig Kapusta, also known as Matt, serves as Director of Genezen Laboratories, Inc. since July 2024. He served as Independent Director at Decibel Therapeutics, Inc. since March 2023 until Septe...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 7.8yrs | US$6.58m | 0.67% $ 1.7m | |
| CFO, Principal Financial Officer & GM of Amsterdam Site | 3.3yrs | US$2.12m | 0.16% $ 385.4k | |
| Chief Business & Scientific Officer | less than a year | US$2.62m | 0.068% $ 168.7k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 1.3yrs | US$2.54m | 0.022% $ 55.5k | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | no data | 데이터 없음 | 데이터 없음 | |
| Chief Technical Operations | less than a year | 데이터 없음 | 데이터 없음 | |
| Business Development Director | 16.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Corporate Affairs Officer | 2.5yrs | US$1.22m | 데이터 없음 | |
| Chief Medical Officer | 1.3yrs | 데이터 없음 | 0.24% $ 585.5k | |
| Vice President of Global Medical Affairs | no data | 데이터 없음 | 데이터 없음 |
1.9yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: QURE 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Executive Director | 9.7yrs | US$6.58m | 0.67% $ 1.7m | |
| Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 10.1yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 4.3yrs | US$412.46k | 0.033% $ 81.3k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 8.3yrs | US$424.96k | 0.013% $ 33.0k | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Non-Executive Director | 7yrs | US$412.46k | 0.049% $ 120.7k | |
| Independent Non-Executive Director | 7yrs | US$424.96k | 0.049% $ 120.7k | |
| Independent Chairman of the Board | 6.3yrs | US$444.96k | 0.042% $ 102.9k | |
| Non-Executive Director | 5.9yrs | US$404.96k | 0.091% $ 224.4k |
7.0yrs
평균 재임 기간
71yo
평균 연령
경험이 풍부한 이사회: QURE 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.